Compare SDGR & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDGR | ALVO |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | N/A |
| Metric | SDGR | ALVO |
|---|---|---|
| Price | $18.14 | $3.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $21.00 | $8.00 |
| AVG Volume (30 Days) | ★ 974.4K | 785.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $255,869,000.00 | N/A |
| Revenue This Year | $0.76 | $13.28 |
| Revenue Next Year | $4.60 | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | ★ 23.29 | N/A |
| 52 Week Low | $10.95 | $2.94 |
| 52 Week High | $23.02 | $9.25 |
| Indicator | SDGR | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 71.63 | 57.03 |
| Support Level | $17.26 | $3.10 |
| Resistance Level | $18.12 | $4.02 |
| Average True Range (ATR) | 0.65 | 0.23 |
| MACD | 0.17 | 0.07 |
| Stochastic Oscillator | 84.88 | 70.37 |
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.